Find information on thousands of medical conditions and prescription drugs.

Hereditary amyloidosis

Amyloid describes various types of protein aggregations that share specific traits when examined microscopically. The name amyloid comes from the early mistaken identification of the substance as starch (amylum in Latin), based on crude iodine-staining techniques. For a period the scientific community debated whether or not amyloid deposits were fatty deposits or carbohydrate deposits until it was finally resolved that it was neither, rather a deposition of proteinaceous mass. more...

Hairy cell leukemia
Hallermann Streiff syndrome
Hallux valgus
Hantavirus pulmonary...
HARD syndrome
Harlequin type ichthyosis
Hartnup disease
Hashimoto's thyroiditis
Hearing impairment
Hearing loss
Heart block
Heavy metal poisoning
HELLP syndrome
Hemifacial microsomia
Hemolytic-uremic syndrome
Hemophilia A
Hemorrhagic fever
Hepatic encephalopathy
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatocellular carcinoma
Hepatorenal syndrome
Hereditary amyloidosis
Hereditary angioedema
Hereditary ataxia
Hereditary ceroid...
Hereditary coproporphyria
Hereditary elliptocytosis
Hereditary fructose...
Hereditary hemochromatosis
Hereditary hemorrhagic...
Hereditary spastic...
Hereditary spherocytosis
Hermansky-Pudlak syndrome
Herpes zoster
Herpes zoster oticus
Hidradenitis suppurativa
Hip dysplasia
Hirschsprung's disease
Hodgkin lymphoma
Hodgkin's disease
Horner's syndrome
Horseshoe kidney
Howell-Evans syndrome
Human parvovirus B19...
Hunter syndrome
Huntington's disease
Hurler syndrome
Hutchinson Gilford...
Hutchinson-Gilford syndrome
Hydatidiform mole
Hydrops fetalis
Hypereosinophilic syndrome
Hyperimmunoglobinemia D...
Hyperkalemic periodic...
Hyperlipoproteinemia type I
Hyperlipoproteinemia type II
Hyperlipoproteinemia type...
Hyperlipoproteinemia type IV
Hyperlipoproteinemia type V
Hypertensive retinopathy
Hypertrophic cardiomyopathy
Hypokalemic periodic...
Hypoplastic left heart...
Hypothalamic dysfunction

Specifically, amyloid deposits are extracellular, thioflavin s positive, and exhibit apple-green birefringence when stained with congo red. Other indicators exist, such as serum amyloid p-component binding. Since these are indirect indicators, biophysicists have redefined amyloid using a canonical set of biophysical characteristics (see below), and this seems to cause a low level of conflict between histologists and biophysicists.

The phenotypes of genetically transmitted amyloid diseases are often inherited in an autosomal dominant fashion. Sometimes, the difference between aggressive amyloid diseases and senescent amyloid diseases is due to a mutation which makes the protein more prone to aggregation. Most commonly seen are point mutations which affect the cohesiveness of the protein and promote misfolding; other mutations cause aggregation-prone pieces of the protein to be cleaved off from the rest of the protein.

Diseases featuring amyloid

It should be noted that in almost all of the organ-specific pathologies, there is significant debate as to whether the amyloid plaques are the causal agent of the disease or if they are instead a symptom downstream of a common ideopathic agent. The associated proteins are indicated in parentheses.

  • Systemic amyloidosis
    • Primary amyloidosis
      • Mutations in lysozyme, transthyretin, apolipoprotein B, fibrinogen
    • Secondary amyloidosis
      • AA amyloidosis (amyloid A protein, an acute phase protein due to chronic inflammation)
      • AL amyloidosis (immunoglobulin light chains)
      • Gelsolin amyloidosis (plasma gelsolin fragments).
    • Familial or Hereditary amyloidosis
      • Most commonly caused by mutations in the transthyretin protein, but in rare occurrences can also be caused by apolipoprotein A1, gelsolin, fibrinogen, and lysozyme mutations.
      • Primarily caused by genetics, believed to be autosomal dominant, high probability of passage to offspring
      • Appalachian type amyloidosis is perhaps the most well known type
  • Organ-specific amyloidosis
    • Diabetes mellitus type 2 (amylin, also known as IAPP)
    • Neurology
      • Alzheimer's disease (Aβ 39-42)
      • Parkinson's disease (alpha-synuclein) -- biophysical definition
      • Huntington's disease (huntingtin) -- biophysical definition
      • Spongiform encephalopathies
        • Creutzfeldt-Jakob disease (PrP in cerebrum)
        • Kuru (diffuse PrP deposits in brain)
        • Fatal Familial Insomnia (PrP in thalamus)
        • Bovine spongiform encephalopathy (PrP in cerebrum)
      • Congophilic angiopathy (Amyloid beta)
      • congestive heart failure; some instances (PrP in heart)
    • Inclusion body myositis
  • Iatrogenic conditions
    • insulin amyloidosis (injection-administered insulin)


[List your site here Free!]

Chronic kidney failure
From Gale Encyclopedia of Medicine, 4/6/01 by Paula Anne Ford-Martin


Chronic kidney failure occurs when disease or disorder damages the kidneys so that they are no longer capable of adequately removing fluids and wastes from the body or of maintaining the proper level of certain kidney-regulated chemicals in the bloodstream.


Chronic kidney failure, also known as chronic renal failure, affects over 250,000 Americans annually. It is caused by a number of diseases and inherited disorders, but the progression of chronic kidney failure is always the same. The kidneys, which serve as the body's natural filtration system, gradually lose their ability to remove fluids and waste products (urea) from the bloodstream. They also fail to regulate certain chemicals in the bloodstream, and deposit protein into the urine. Chronic kidney failure is irreversible, and will eventually lead to total kidney failure, also known as end-stage renal disease (ESRD). Without proper treatment intervention to remove wastes and fluids from the bloodstream, ESRD is fatal.

Causes & symptoms

Kidney failure is triggered by disease or a hereditary disorder in the kidneys. Both kidneys are typically affected. The four most common causes of chronic kidney failure include:

  • Diabetes. Diabetes mellitus (DM), both insulin dependant (IDDM) and non-insulin dependant (NIDDM), occurs when the body cannot produce and/or use insulin, the hormone necessary for the body to process glucose. Long-term diabetes may cause the glomeruli, the filtering units located in the nephrons of the kidneys, to gradually lose functioning.
  • Glomerulonephritis. Glomerulonephritis is a chronic inflammation of the glomeruli, or filtering units of the kidney. Certain types of glomerulonephritis are treatable, and may only cause a temporary disruption of kidney functioning.
  • Hypertension. High blood pressure is unique in that it is both a cause and a major symptom of kidney failure. The kidneys can become stressed and ultimately sustain permanent damage from blood pushing through them at an excessive level of pressure over a long period of time.
  • Polycystic kidney disease. Polycystic kidney disease is an inherited disorder that causes cysts to be formed on the nephrons, or functioning units, of the kidneys. The cysts hamper the regular functioning of the kidney.

Other possible causes of chronic kidney failure include kidney cancer, obstructions such as kidney stones, pyelonephritis, reflux nephropathy, systemic lupus erythematosus, amyloidosis, sickle cell anemia, Alport syndrome, and oxalosis.

Initially, symtpoms of chronic kidney failure develop slowly. Even individuals with mild to moderate kidney failure may show few symtpoms in spite of increased urea in their blood. Among the symptoms that may be present at this point are frequent urination during the night and high blood pressure.

Most symptoms of chronic kidney failure are not apparent until kidney disease has progressed significantly. Common symptoms include:

  • Anemia. The kidneys are responsible for the production of erythropoietin (EPO), a hormone which stimulates red cell production. If kidney disease causes shrinking of the kidney, this red cell production is hampered.
  • Bad breath or a bad taste in mouth. Urea, or waste products, in the saliva may cause an ammonia-like taste in the mouth.
  • Bone and joint problems. The kidneys produce vitamin D, which aids in the absorption of calcium and keeps bones strong. For patients with kidney failure, bones may become brittle, and in the case of children, normal growth may be stunted. Joint pain may also occur as a result of unchecked phosphate levels in the blood.
  • Edema. Puffiness or swelling around the eyes, arms, hands, and feet.
  • Frequent urination.
  • Foamy or bloody urine. Protein in the urine may cause it to foam significantly. Blood in the urine may indicate bleeding from diseased or obstructed kidneys, bladder, or ureters.
  • Headaches. High blood pressure may trigger headaches.
  • Hypertension, or high blood pressure. The retention of fluids and wastes causes blood volume to increase, which in turn, causes blood pressure to rise.
  • Increased fatigue. Toxic substances in the blood and the presence of anemia may cause feelings of exhaustion.
  • Itching. Phosphorus, which is typically eliminated in the urine, accumulates in the blood of patients with kidney failure. This heightened phosphorus level may cause itching of the skin.
  • Lower back pain. Pain where the kidneys are located, in the small of the back below the ribs.
  • Nausea, loss of appetite, and vomiting. Urea in the gastric juices may cause upset stomach. This can lead to malnutrition and weight loss.


Kidney failure is typically diagnosed and treated by a nephrologist, a doctor that specializes in treating the kidneys. The patient that is suspected of having chronic kidney failure will undergo an extensive blood work-up. A blood test will assess the levels of creatinine, blood urea nitrogen (BUN), uric acid, phosphate, sodium, and potassium in the blood. Urine samples will also be collected, usually over a 24-hour period, to assess protein loss.

Uncovering the cause of kidney failure is critical to proper treatment. A full assessment of the kidneys is necessary to determine if the underlying disease is treatable and if the kidney failure is chronic or acute. An x ray, MRI, computed tomography scan, ultrasound, renal biopsy, and/or arteriogram of the kidneys may be employed to determine the cause of kidney failure and level of remaining kidney function. X rays and ultrasound of the bladder and/or ureters may also be taken.


Chronic kidney failure is an irreversible condition. Hemodialysis, peritoneal dialysis, or kidney transplantation must be employed to replace the lost function of the kidneys. In addition, dietary changes and treatment to relieve specific symptoms such as anemia and high blood pressure are critical to the treatment process.


Hemodialysis is the most frequently prescribed type of dialysis treatment in the United States. Most hemodialysis patients require treatment three times a week, for an average of three to four hours per dialysis "run" depending on the type of dialyzer used and their current physical condition. The treatment involves circulating the patient's blood outside of the body through an extracorporeal circuit (ECC), or dialysis circuit. The dialysis circuit consists of plastic blood tubing, a two-compartment filter known as a dialyzer, or artificial kidney, and a dialysis machine that monitors and maintains blood flow and administers dialysate, a chemical bath used to draw waste products out of the blood. The patient's blood leaves and enters the body through two needles inserted into the patient's vein, called an access site, and is pushed through the blood compartment of the dialyzer. Once inside of the dialyzer, excess fluids and toxins are pulled out of the bloodstream and into the dialysate compartment, where they are carried out of the body. At the same time, electrolytes and other chemicals in the dialysate solution move from the dialysate into the bloodstream. The purified, chemically-balanced blood is then returned to the body.

Peritoneal dialysis

In peritoneal dialysis (PD), the patient's peritoneum, or lining of the abdomen, acts as a blood filter. A catheter is surgically inserted into the patient's abdomen. During treatment, the catheter is used to fill the abdominal cavity with dialysate. Waste products and excess fluids move from the patient's bloodstream into the dialysate solution. After a waiting period of 6 to 24 hours, depending on the treatment method used, the waste-filled dialysate is drained from the abdomen, and replaced with clean dialysate. There are three types of peritoneal dialysis, which vary by treatment time and administration method: Continuous Ambulatory Peritoneal Dialysis (CAPD), Continuous Cyclic Peritoneal Dialysis (CCPD), and Intermittent Peritoneal Dialysis (IPD).

Kidney transplantation

Kidney transplantation involves surgically attaching a functioning kidney, or graft, from a brain dead organ donor (a cadaver transplant), or from a living donor, to a patient with ESRD. Patients with chronic renal disease who need a transplant and don't have a living donor register with UNOS (United Network for Organ Sharing), the federal organ procurement agency, to be placed on a waiting list for a cadaver kidney transplant. Kidney availability is based on the patient's health status. When the new kidney is transplanted, the patient's existing, diseased kidneys may or may not be removed, depending on the circumstances surrounding the kidney failure. A regimen of immunosuppressive, or anti-rejection medication, is required after transplantation surgery.

Dietary management

A diet low in sodium, potassium, and phosphorous, three substances that the kidneys regulate, is critical in managing kidney disease Other dietary restrictions, such as a reduction in protein, may be prescribed depending on the cause of kidney failure and the type of dialysis treatment employed. Patients with chronic kidney failure also need to limit their fluid intake.

Medications and dietary supplements

Kidney failure patients with hypertension typically take medication to control their high blood pressure. Epoetin alfa, or EPO (Epogen), a hormone therapy, and intravenous or oral iron supplements are used to manage anemia. A multivitamin may be prescribed to replace vitamins lost during dialysis treatments. Vitamin D, which promotes the absorption of calcium, along with calcium supplements, may also be prescribed.

Since 1973, Medicare has picked up 80% of ESRD treatment costs, including the costs of dialysis and transplantation and of some medications. To qualify for benefits, a patient must be insured or eligible for benefits under Social Security, or be a spouse or child of an eligible American. Private insurance and state Medicaid programs often cover the remaining 20% of treatment costs.


Early diagnosis and treatment of kidney failure is critical to improving length and quality of life in chronic kidney failure patients. Patient outcome varies by the cause of chronic kidney failure and the method chosen to treat it. Overall, patients with chronic kidney disease leading to ESRD have a shortened life span. According to the United States Renal Data System (USRDS), the life span of an ESRD patient is 18-47% of the life span of the age-sex-race matched general population. ESRD patients on dialysis have a life span that is 16-37% of the general population

The demand for kidneys to transplant continues to exceed supply. In 1996, over 34,000 Americans were on the UNOS waiting list for a kidney transplant, but only 11,330 living donor and cadaver transplants were actually performed. Cadaver kidney transplants have a 50% chance of functioning 9 years, and living donor kidneys that have two matching antigen pairs have a 50% chance of functioning for 24 years. However, some transplant grafts have functioned for over 30 years.

Key Terms

End-stage renal disease (ESRD)
Total kidney failure; chronic kidney failure is diagnosed as ESRD when kidney function falls to 5-10% of capacity.
Nephrotic syndrome
Characterized by protein loss in the urine, low protein levels in the blood, and fluid retention.
The two ducts that pass urine from each kidney to the bladder.

Further Reading

For Your Information


  • Bock, G.H., E.J. Ruley, and M.P. Moore. A Parent's Guide to Kidney Disorders. Minneapolis, MN: Univ. of Minnesota Press, 1993.
  • Brenner, Barry M. and Floyd C. Rector, Jr. ,eds. The Kidney. Philadelphia: W.B. Saunders Company, 1991.
  • Cameron, J.S. Kidney Failure: The Facts. New York: Oxford Univ. Press, 1996.
  • Ross, Linda M., ed. Kidney and Urinary Tract Diseases and Disorders Sourcebook. Vol. 21. Health Reference Series. Detroit: Omnigraphics, 1997.
  • U.S. Renal Data System. USRDS 1997 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1996. (Available in paper and microfiche versions from National Technical Information Service (NTIS), Springfield, VA.)


  • Friedman, Elia A. "End-stage Renal Disease Therapy: An American Success Story." Journal of the American Medical Association 275(April 1996): 1118-22.
  • Taylor, Judy H. "End-stage Renal Disease in Children: Diagnosis, Management, and Interventions." Pediatric Nursing 22(Nov-Dec 1996): 481-92.


  • American Association of Kidney Patients (AAKP). 100 S. Ashley Drive, Suite 280, Tampa, FL 33602. (800)749-2257.
  • American Kidney Fund (AKF). Suite 1010, 6110 Executive Boulevard, Rockville, MD 20852. (800)638-8299.
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Natcher Building - 6AS-13K, 45 Center Drive, Bethesda, MD 20892-6600.
  • National Kidney Foundation (NKF). 30 East 33rd Street, New York, NY 10016. (800)622-9020.
  • United States Renal Data System (USRDS). USRDS Coordinating Center, 315 W. Huron, Suite 240, Ann Arbor, MI 48103. (313)998-6611.

Gale Encyclopedia of Medicine. Gale Research, 1999.

Return to Hereditary amyloidosis
Home Contact Resources Exchange Links ebay